Pharming Group (NASDAQ:PHAR) Hits New 1-Year Low at $9.35

Pharming Group (NASDAQ:PHAR) hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $9.35 and last traded at $9.35, with a volume of 665 shares changing hands. The stock had previously closed at $10.17.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a report on Thursday, March 14th.

Pharming Group Price Performance

The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $626.11 million, a price-to-earnings ratio of -66.79 and a beta of 0.16. The stock has a 50-day moving average price of $11.09 and a 200 day moving average price of $11.52.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.08). Pharming Group had a negative return on equity of 4.53% and a negative net margin of 4.13%. The firm had revenue of $81.20 million during the quarter, compared to analyst estimates of $71.83 million. As a group, equities research analysts expect that Pharming Group will post -0.02 earnings per share for the current year.

Institutional Trading of Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. Orion Portfolio Solutions LLC purchased a new position in Pharming Group (NASDAQ:PHAR) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,715 shares of the company’s stock, valued at approximately $134,000. 0.03% of the stock is owned by hedge funds and other institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks.